Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Incidental DWI-Positive Lesions in 2 Cohorts of CAA and CADASIL: Prevalence, Distribution, and Associations With Clinical Variables.

Neurology·2026
Same author

Brain regional susceptibility to tauopathy in individuals at risk for chronic traumatic encephalopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Differential associations of plasma biomarkers with Alzheimer's disease and small vessel disease: A multimodal imaging study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Expanding the Clinicoradiologic Phenotype of the <i>CTSA</i>-Associated Small Vessel Disease CARASAL: A Comparison With CADASIL.

Neurology. Genetics·2026
Same author

3D Vessels-on-Chip using isogenic hiPSC-derived VSMCs reveal NOTCH3-driven alterations in brain small vessel disease.

Stem cell reports·2026
Same author

Biomarkers for advancing diagnosis and prognosis in stroke.

The Lancet. Neurology·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Anna Dewenter1, Benno Gesierich2, Anna Kopczak3

  • 1Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Bavaria, Germany.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

一种新的扩散MRI标记物PSMD-2增强了检测小血管疾病 (SVD) 脑部变化的灵敏度. 这种改进的标记物减少了临床试验的样本大小要求,有助于监测SVD进展.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经成像是一种神经成像.
  • 扩散式核磁共振成像 (MRI)
  • 脑血管疾病 脑血管疾病

背景情况:

  • 小血管疾病 (SVD) 在老年人中很常见,与阿尔茨海默病有关.
  • 传统的MRI标记器检测到晚期SVD阶段;扩散MRI指标识别早期变化.
  • 骨化平均扩散率 (PSMD) 的峰值宽度是SVD的既定扩散MRI标志物.

研究的目的:

  • 开发一种改进的扩散MRI标记物PSMD-2,用于对SVD进行纵向评估.
  • 为了提高SVD临床试验的灵敏度和减少样本大小要求.

主要方法:

  • PSMD-2是使用自由水校正的扩散图,主体内模板和常见骨开发的.
  • 包括120名具有家族性SVD (CADASIL) 的受试者进行开发和89名受试者 (CADASIL,零星SVD) 进行验证.
  • 通过估计假设临床试验的样本大小减少,将PSMD-2与PSMD进行比较.

主要成果:

  • 在所有研究队列中,PSMD-2有效跟踪了疾病的进展.
  • PSMD-2显示了所需样本大小的显著减少:24.3% (发展),31.0% (验证CADASIL) 和18.6% (验证零星SVD).
  • 持续的验证包括脑粉样血管病变和可重复性/可重复性评估.

结论:

  • 与PSMD相比,PSMD-2在检测与SVD相关的大脑变化方面具有更高的灵敏度.
  • 该标记物显著减少了样本大小的需求,使其成为SVD临床试验的理想选择.
  • PSMD-2对于监测SVD进展和阿尔茨海默病的并发性血管变化非常有价值.